RJFSA
CORT icon

Raymond James Financial Services Advisors’s Corcept Therapeutics CORT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-77,593
Closed -$2.52M – 3463
2024
Q2 		$2.52M Buy
77,593
+27,488
+55% +$753K ﹤0.01% 1539
2024
Q1 		$1.26M Buy
+50,105
New +$1.18M ﹤0.01% 1925

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Raymond James Financial Services Advisors's CORT Position: Q3 2024 in Review

Raymond James Financial Services Advisors sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 77,593 shares — an estimated $2.52M sold.

Raymond James Financial Services Advisors first reported a position in CORT in Q1 2024 and held it in 2 quarters. The position peaked at $2.52M in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Raymond James Financial Services Advisors reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 77,593 Corcept Therapeutics shares in Q3 2024, an estimated $2.52M.
  • Raymond James Financial Services Advisors first reported a position in Corcept Therapeutics in Q1 2024 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Corcept Therapeutics position peaked at $2.52M in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.